Adverse effects of medical cannabinoids: a systematic review

Tongtong Wang; Collet, Jean-Paul; Shapiro, Stan; Ware, Mark A.
June 2008
CMAJ: Canadian Medical Association Journal;6/17/2008, Vol. 178 Issue 13, p1669
Academic Journal
Background: The therapeutic use of cannabis and cannabis-based medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods: We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated the quality of published studies with a view to identifying ways to improve future studies. Results: A total of 321 articles were eligible for evaluation. After excluding those that focused on recreational cannabis use, we included 31 studies (23 randomized controlled trials and 8 observational studies) of medical cannabis use in our analysis. In the 23 randomized controlled trials, the median duration of cannabinoid exposure was 2 weeks (range 8 hours to 12 months). A total of 4779 adverse events were reported among participants assigned to the intervention. Most (4615 [96.6%]) were not serious. Of the 164 serious adverse events, the most common was relapse of multiple sclerosis (21 events [12.8%]), vomiting (16 events [9.8%]) and urinary tract infection (15 events [9.1%]). The rate of nonserious adverse events was higher among participants assigned to medical cannabinoids than among controls (rate ratio [RR] 1.86, 95% confidence interval [CI] 1.57-2.21); the rates of serious adverse events did not differ significantly between these 2 groups (RR 1.04, 95% CI 0.78-1.39). Dizziness was the most commonly reported nonserious adverse event (714 events [15.5%]) among people exposed to cannabinoids. Interpretation: Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events. The risks associated with long-term use were poorly characterized in published clinical trials and observational studies. High-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.


Related Articles

  • Therapeutic Potential of Cannabinoids in Trigeminal Neuralgia. Ying-Ching Liang; Chiung-Chun Huang; Kuei-Sen Hsu // Current Drug Targets - CNS & Neurological Disorders;Dec2004, Vol. 3 Issue 6, p507 

    Trigeminal neuralgia is a disorder of paroxysmal and severely disabling facial pain and continues to be a real therapeutic challenge to the clinicians. While the exact cause and pathology of this disorder is uncertain, it is thought that trigeminal neuralgia caused by irritation of the...

  • The adverse effects of cannabinoids: implications for use of medical marijuana. Degenhardt, Louisa; Hall, Wayne D. // CMAJ: Canadian Medical Association Journal;6/17/2008, Vol. 178 Issue 13, p1685 

    The authors reflects on the impact of using cannabis for medical purposes. The authors infers that the current review of evidence from clinical trials of cannabinoids and cannabis extracts for medical indications suggests that the adverse effects of their short-term use are modest. The authors...

  • Recreational drugs go straight. de Lange, Catherine // New Scientist;9/4/2010, Vol. 207 Issue 2776, p1 

    The article discusses contemporary research on medicinal uses of LSD, a drug discovered by chemist Albert Hofmann in 1938 that became classified as a so-called schedule 1 drug of abuse in 1970 by the U.S. Food and Drug Administration (FDA). Beckley Foundation director Amanda Feilding and...

  • Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease. Sagredo, Onintza; Pazos, M. Ruth; Valdeolivas, Sara; Fernández-Ruiz, Javier // Recent Patents on CNS Drug Discovery;Apr2012, Vol. 7 Issue 1, p41 

    Cannabinoid pharmacology has experienced a notable increase in the last 3 decades which is allowing the development of novel cannabinoid-based medicines for the treatment of different human pathologies, for example, Cesamet® (nabilone) or Marinol® (synthetic Δ9-tetrahydrocannabinol for...

  • Californian centre will test medical uses of cannabis. Dalton, Rex // Nature;9/7/2000, Vol. 407 Issue 6800, p6 

    Reports that the Center for Medicinal Cannabis Research is being set up by the University of California to study the drug's efficacy and safety. Study of the effects of marijuana on diseases such as AIDS, muscle spasticity, and nausea caused by cancer treatment; Funds for the research; Details...

  • The Medicinal Use of Cannabis and Cannabinoids--An International Cross-Sectional Survey on Administration Forms. Hazekamp, Arno; Ware, Mark A.; Muller-Vahl, Kirsten R.; Abrams, Donald; Grotenhermen, Franjo // Journal of Psychoactive Drugs;Jul/Aug2013, Vol. 45 Issue 3, p199 

    Cannabinoids, including tetrahydrocannabinol and cannabidiol, are the most important active constituents of the cannabis plant. Over recent years, cannabinoid-based medicines (CBMs) have become increasingly available to patients in many countries, both as pharmaceutical products and as herbal...

  • Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats. Farrimond, Jonathan A.; Hill, Andrew J.; Whalley, Benjamin J.; Williams, Claire M. // Psychopharmacology;Jun2010, Vol. 210 Issue 1, p97 

    The hyperphagic effect of ∆9-tetrahydrocannabinol (∆9THC) in humans and rodents is well known. However, no studies have investigated the importance of ∆9THC composition and any influence other non-∆9THC cannabinoids present in Cannabis sativa may have. We therefore...

  • The Fallacy of a One Size Fits All Cannabis Policy. Reiman, Amanda // Humboldt Journal of Social Relations;2013, Vol. 35 Issue 1, p104 

    Although the cannabis plant is one of the oldest herbal products currently in use, the policies and research surrounding its use and associated risks and benefits have been points of contention throughout its modern lifespan. Cannabis has been seen as a revered botanical medicine, a demon...

  • A sane solution to an irrational standoff. BOSTWICK, J. MICHAEL // Minnesota Medicine;Apr2014, Vol. 97 Issue 4, p36 

    The author discusses the designation of cannabis as a Schedule 1 drug indicating it had no medical value and a high risk of abuse. He notes how current medical marijuana products challenges ideas on what constitutes a legitimate medication He indicates that rescheduling cannabis as Schedule 2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics